The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Ligand-induced ErbB receptor dimerization
Open accessAbstract
Structural studies have provided important new insights into how ligand binding promotes homodimerization and activation of the EGF receptor and the other members of the ErbB family or receptor tyrosine kinases. These structures have also suggested possible explanations for the unique properties of ErbB2, which has no known ligand and can cause cell transformation (and tumorigenesis) by simple overexpression. In parallel with these advances, studies of the EGF receptor at the cell surface increasingly argue that the structural studies are missing key mechanistic components. This is particularly evident in the structural prediction that EGF binding linked to receptor dimerization should be positively cooperative, whereas cell-surface EGF-binding studies suggest negative cooperativity. In this review, I summarize studies of ErbB receptor extracellular regions in solution and of intact receptors at the cell surface, and attempt to reconcile the differences suggested by the two approaches. By combining results obtained with receptor ‘parts’, it is qualitatively possible to explain some models for the properties of the whole receptor. These considerations underline the need to consider the intact ErbB receptors as intact allosterically regulated enzymes, and to combine cellular and structural studies into a complete picture.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 1×
“ErbB2 overexpression is also strongly associated with breast cancer [35] –and it is the target of the Herceptin antibody [15, 36].”
BackgroundUntangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974 · cited 1×
“Although the mechanism is currently far from clear [9], it is also thought that the four ErbB receptors form an array of heterodimers upon ligand binding [10], potentially thus increasing the complexity of signaling by this family.”
BackgroundSignal transduction by receptors with tyrosine kinase activity
Ullrich, A., & Schlessinger, J. (1990) · Cell · doi:10.1016/0092-8674(90)90801-k · Cited by 5,435
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774 · cited 2×
“In considering the EGFR as an allosteric enzyme as outlined above, it is to be expected that it may dimerize significantly in the absence of ligand [8].”
BackgroundAn allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Zhang, X., Gureasko, J., Shen, K., Cole, P. A., & Kuriyan, J. (2006) · Cell · doi:10.1016/j.cell.2006.05.013 · Cited by 1,650 · cited 10×
“The structures of extracellular regions described here, and of intracellular regions reviewed by Bose and Zhang [84], have provided the essential tools for generating detailed hypotheses.”
BackgroundInfluentialTargeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00097-1 · Cited by 873 · cited 1×
“By contrast, several studies at the cell surface have demonstrated – with intact receptors or various chimerae – robust association of ErbB2 with EGFR [40] and ErbB3 [39,40,42] in a cellular context, in response to EGF and neuregulin respectively.”
BackgroundYarden, Y., & Schlessinger, J. (1987) · Biochemistry · doi:10.1021/bi00379a035 · Cited by 627
Cited by
The EGFR Family: Not So Prototypical Receptor Tyrosine Kinases
Lemmon, M. A., Schlessinger, J., & Ferguson, K. M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020768 · Cited by 475
Self-citationWang, Z. (2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-7219-7_1 · Cited by 430
Liu, Y.-C., Yen, H.-Y., Chen, C.-Y., Chen, C.-H., Cheng, P.-F., Juan, Y.-H., Chen, C.-H., Khoo, K.-H., Yu, C.-J., Yang, P.-C., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107385108 · Cited by 424
“It belongs to the EGFR family and transduces cell signaling through ligand (EGF)-induced receptor dimerization (4), which then initiates its tyrosine kinase activity to direct the malignant behaviors of cancers (5).”
BackgroundSpatial regulation of receptor tyrosine kinases in development and cancer
Casaletto, J. B., & McClatchey, A. I. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3277 · Cited by 359
Goodson, W. H., Lowe, L., Carpenter, D. O., Gilbertson, M., Manaf Ali, A., Lopez de Cerain Salsamendi, A., Lasfar, A., Carnero, A., Azqueta, A., Amedei, A., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv039 · Cited by 322
The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain
Red Brewer, M., Choi, S. H., Alvarado, D., Moravcevic, K., Pozzi, A., Lemmon, M. A., & Carpenter, G. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.04.034 · Cited by 317
Self-citationEck, M. J., & Yun, C.-H. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.12.010 · Cited by 225
Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition
Yen, H.-Y., Liu, Y.-C., Chen, N.-Y., Tsai, C.-F., Wang, Y.-T., Chen, Y.-J., Hsu, T.-L., Yang, P.-C., & Wong, C.-H. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1507329112 · Cited by 119
The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein
Lucas, L. M., Dwivedi, V., Senfeld, J. I., Cullum, R. L., Mill, C. P., Piazza, J. T., Bryant, I. N., Cook, L. J., Miller, S. T., Lott, J. H., et al. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000381 · Cited by 70
“…Roskoski, 2004, 2014; Bouyain et al., 2005; Dawson et al., 2005; Citri and Yarden, 2006; Ozcan et al., 2006; Britsch, 2007; Riese et al., 2007; Lemmon, 2009; Lemmon and Schlessinger, 2010; Rudloff and Samuels, 2010; Alaoui-Jamali et al., 2015; Appert-Collin et al., 2015; Feldinger and Kong,…”
BackgroundInfluentialHER3 Alterations in Cancer and Potential Clinical Implications
Kilroy, M. K., Park, S., Feroz, W., Patel, H., Mishra, R., Alanazi, S., & Garrett, J. T. (2022) · Cancers · doi:10.3390/cancers14246174 · Cited by 21
Metadata
- Authors
- Lemmon, M. A.
- Venue
- Experimental Cell Research
- Publisher
- Elsevier BV
- Published
- 2009-02
- Volume
- 315
- Issue
- 4
- Pages
- 638-648
- ISSN
- 0014-4827 (ISSN-L)
- OpenAlex
- W2063917536
- Cited by
- 216
- References
- 7
- FWCI
- 8.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.